I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

The routine methods for measuring total calcium include azo arsenic III colorimetry, O-cresolphthalein complexone (OCPC) colorimetry, and the methylthymol blue colorimetric method. The IFCC recommends isotope dilution mass spectrometry as a decisive method and atomic absorption spectrometry as a reference method.

Compared with reference methods, routine methods are easy to automate, making them suitable for clinical laboratories. However, routine methods may exhibit weaknesses such as unsatisfactory specificity and a traceability chain\[[@ref1]\] that is not intact, which may affect the accuracy of measurement results. Therefore, it is necessary to evaluate the performance of the routine methods commercialized by different manufacturers. Assessment of the variability of the measurement results obtained by different assays and the effectiveness of standardization is best accomplished through external quality assessment (EQA), or proficiency testing (PT), schemes.\[[@ref2][@ref3][@ref4]\] The ideal EQA materials and calibrators need to be commutable or the commutability must be known to ensure that the objective of evaluating the comparability of different assays is fulfilled.\[[@ref5][@ref6]\] However, for practical reasons, most PT schemes use processed materials with unknown commutability.

We designed the present study according to the following recommendations made by the Clinical and Laboratory Standards Institute: EP14-A2\[[@ref7]\] and EP9-A2.\[[@ref8]\] The study involved the measurement of processed materials as well as a set of individual patient samples using comparative and routine methods. By evaluating the commutability of processed materials, we can interpret our PT results and search for possible commutable materials. In addition, the results of the 48 patient serum samples were used to assess the accuracy of routine measures and can provide insight into the potential insufficiency of these methods.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study involved using leftover patient samples, and the leftover patient samples were all de-identified during the collection. It was also ensured that the appropriate amount of serum was collected from each patient sample so that a certain volume was left for possible repetition of measurement. The use of patient samples in the present study has been reviewed and approved by the Ethics Committee of Beijing Hospital, and the need for consent with the donors was waived.

Individual patient samples {#sec2-2}
--------------------------

De-identified patient samples with concentrations ranging from 1.83 mmol/L to 3.10 mmol/L (measured by the Beckman Access Assay AU5400 at Beijing Hospital) were collected. Each of the samples was split into three aliquots and frozen at −80°C. Two aliquots were detected by the reference method, and one aliquot was detected by the 14 types of routine methods.

Processed materials {#sec2-3}
-------------------

**EQA materials**

The control materials used in our 2013 EQA schemes (purchased from BIO-RAD. Co) and 2014 EQA schemes (purchased from Randox Co.) were designated EQA201331-201335 and EQA201411-201415, respectively. The matrix used was lyophilized human serum. The materials were dissolved, vialed, and frozen at −80°C.

**Calibrators**

Four types of calibrators, designated Imported A, Imported B, Domestic A, and Domestic B, were all lyophilized serum. The calibrators were dissolved, vialed, and frozen at −80°C.

**Human serum pools**

Human serum pools were prepared from 200 leftover patient serum samples collected from clinical laboratories at Beijing Hospital. The pools were then mixed and divided into two parts: low-concentration serum was prepared by adding 7% water and high-concentration serum was prepared by adding a standard reference material (NIST SRM 3109a). The target values for the low and high concentrations assigned by inductively coupled plasma-mass spectrometry (ICP-MS) were 2.06 mmol/L and 3.06 mmol/L, respectively. After dispensing, the mixed pools were blended overnight at 4°C and then vialed and frozen at −80°C.

**Certified reference materials**

Three reference materials were used: GBW 09152 (fresh frozen serum) purchased from the National Institute of Metrology, China, with a concentration of 2.425 ± 0.051mmol/L; BCR304 (lyophilized serum) purchased from the European Commission\'s Joint Research Center with a concentration of 2.201 ± 0.019 mmol/L; and SRM956C2 (fresh frozen serum) obtained from the National Institute of Standards and Technology with a concentration of 2.538 ± 0.016 mmol/L.

**Aqueous reference materials**

The standard material SRM3109a (Ca) was spiked into 5% nitric acid to achieve five suitable concentrations and assigned as NC 1--5.

**Animal materials**

The swine sera samples were obtained as gifts from the Research Center for Coronary Heart Disease, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences.

Comparative method (reference method) {#sec2-4}
-------------------------------------

ICP-MS was used as the comparative method with aluminum selected as an internal standard.

The method was established by the National Center of Clinical Laboratory and was described in the previous paper.\[[@ref9]\] All of the samples (48 patient samples and 25 processed materials) were divided into 12 subsets and detected over a period of 12 days.

Test methods (routine methods) {#sec2-5}
------------------------------

Among the 14 routine methods, three were from foreign companies (Roche, Diasys, and Wako), and the others were from Chinese companies (Sichuan Maccura, Beijing Strong, DIRUI, Leadman, Mindray, Shanghai Fosun Long March, Kehua, Reebio, Biosino, Long March I (OCPC), and Long March II \[the azo arsenic III method\]). All tests were completed on a Hitachi 7180 automatic biochemical analyzer and the parameters were set in accordance with the manufacturer\'s instructions. Calibration was performed with supporting calibrators before the measurements. All of the samples were detected twice, and their order of measurement was reversed in the replicate run.

Statistical analysis {#sec2-6}
--------------------

The results from the 48 patient samples were used to generate a scatter plot, with the results of ICP-MS plotted on the X-axis and the results of the 14 routine methods plotted on the Y-axis. The scatter plot was used to calculate the slope, intercept, correlation coefficient, and 95% prediction intervals of each regression line. The commutability of the processed materials was evaluated by comparing the plots (for each of the processed materials) with the limits of the intervals.

The comparison results of the 48 patient serum samples were used to evaluate the measurement accuracy. The results of ICP-MS were used as the target value to calculate the bias of the 14 assays, and the regression line was used to calculate the expected bias at three concentration levels. The following two criteria were used to evaluate bias: the minimum performance standard derived from biological variation (1.3%)\[[@ref10]\] and the expanded tolerance limits based on biological variation and the current quality condition (2%). All of the analyses were performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Precision of the test methods {#sec2-7}
-----------------------------

For the routine methods, each sample was measured twice, and the coefficient of variation (CV) was calculated from the two repeated results. With the exception of the DIRUI (1.96%) and Kehua (2.26%) assays, the mean CV of the other assays met the minimum performance criteria derived from biological variation (1.40%),\[[@ref10]\] indicating that the precision of most of the assays was satisfactory.

Commutability of processed materials {#sec2-8}
------------------------------------

The commutability of the processed materials was evaluated by comparing the plots with the limits of the intervals. A positive matrix effect means that the bias% was higher than the 95% prediction intervals, and a negative matrix effect means that the bias% was lower than the 95% prediction intervals. Because the concentrations of EQA201334, NC4, and NC5 were higher than those of the 48 patient samples, they were not evaluated.

The 2013 EQA samples exhibited a negative matrix effect in some assays, primarily in domestic systems. The commutability of the 2014 EQA samples was relatively high, and only 2014--2015 exhibited a positive matrix effect in some assays. The human serum pools were commutable in all assays. The analysis of the three certificated reference materials revealed the following: GBW09152 exhibited a matrix effect only in Sichuan Maccura and 956c-2 and BCR304 were commutable in all systems. The analysis of the four calibrators revealed that Imported A exhibited a negative matrix effect in some assays, Imported B exhibited a positive matrix effect in some assays, and the two domestic calibrators exhibited a matrix effect in two imported assays and were commutable in all domestic assays. The aqueous reference materials were noncommutable in most assays and could thus only be used as reference methods. The animal sera showed a matrix effect in some assays. The commutability of the processed materials is shown in [Table 1](#T1){ref-type="table"}.

###### 

Commutability of processed materials

  Prepared materials   Roche   Diasys   Wako   Medical system   Sichuan Maccura   Beijing strong   Didui   Leadman   Mindray   Long March I   Long March II   Kehua   Reebio   Biosino
  -------------------- ------- -------- ------ ---------------- ----------------- ---------------- ------- --------- --------- -------------- --------------- ------- -------- ---------
  201331               0       2        0      0                0                 0                0       0         2         0              0               0       0        0
  201332               0       0        0      0                0                 0                0       0         0         0              0               2       0        0
  201333               0       0        0      0                0                 0                0       2         2         0              0               0       0        0
  201335               0       0        0      0                0                 0                0       0         2         0              0               2       0        0
  201411               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  201412               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  201413               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  201414               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  201415               1       1        0      0                0                 0                0       0         0         1              0               0       0        1
  HSP1                 0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  HSP2                 0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  Imported A           0       0        2      0                2                 0                0       0         0         2              0               0       0        2
  Imported B           1       1        0      0                0                 1                0       0         0         0              1               0       0        0
  Domestic A           0       1        0      0                0                 0                0       0         0         0              0               0       0        0
  Domestic B           1       1        0      0                0                 0                0       0         0         0              0               0       0        0
  GBW                  0       0        0      0                1                 0                0       0         0         0              0               0       0        0
  956C-2               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  BCR304               0       0        0      0                0                 0                0       0         0         0              0               0       0        0
  NC1                  1       2        1      0                0                 2                2       2         2         2              2               2       2        0
  NC2                  1       2        1      0                0                 2                2       2         2         2              2               2       2        0
  NC3                  1       2        1      0                0                 2                2       2         2         0              2               2       2        1
  Animal               0       2        0      0                2                 0                0       2         0         1              2               0       0        0

The commutability of the processed materials was evaluated by comparing the plots with the limits of the intervals. The positive matrix effect means a bias% higher than 95% prediction intervals and the negative matrix effect means a bias% lower than the 95% prediction intervals. Furthermore, "0", "1'', and "2" denote commutable, positive matrix effect and negative matrix effect, respectively.

Evaluation accuracy of routine methods {#sec2-9}
--------------------------------------

**Linear regression**

With the exception of the Sichuan Marker assays (*r* = 0.9887), the correlation coefficients were all \>0.99. The slopes ranged from 0.8949 to 1.1078, and most were close to 1% ± 5%; the range of intercepts was −0.2964--0.2585 mmol/L. The specificity of most assays was sufficient; however, the trueness of some assays needs improvement. The linear equations, correlation coefficients, and residual standard deviation Sy. x are presented in [Table 2](#T2){ref-type="table"}.

###### 

Linear regression of the 14 evaluation assays

  Assays                Regression lines       *CI* of slope     *CI* of intercept (mmol/L)   *r*      Sy.x
  --------------------- ---------------------- ----------------- ---------------------------- -------- --------
  Roche                 Y = 0.9666X + 0.0550   0.9489--0.9844    0.0141--0.0960               0.9981   0.0164
  Diasys                Y = 0.9487X + 0.0387   0.9373--0.9602    −0.0108--0.0882              0.9971   0.0198
  Wako                  Y = 1.0002X − 0.0748   0.9848--1.0155    −0.1413--−0.0083             0.9954   0.0267
  Medical system        Y = 0.9526X + 0.0613   0.9366--0.9687    −0.0082--0.1307              0.9945   0.0278
  Sichuan Maccura       Y = 0.9202X + 0.0538   0.8980--0.9424    −0.0422--0.1498              0.9887   0.0389
  Beijing strong        Y = 1.0187X − 0.0614   1.0057--1.0317    −0.1177--−0.0052             0.9968   0.0225
  DIRUI                 Y = 1.0509X − 0.1673   1.0395--1.0624    −0.2169--−0.1177             0.9977   0.0199
  Leadman               Y = 0.9465X + 0.0544   0.9274--−0.9656   −0.0284--0.1371              0.9920   0.0332
  Mindray               Y = 0.9630X + 0.0839   −0.9506--0.9754   0.0303--0.1376               0.9967   0.0215
  Please Long March I   Y = 1.1078X − 0.2964   1.0939--1.1218    −0.3567--−0.2361             0.9969   0.0242
  Long March II         Y = 0.9575X + 0.0459   0.9458--0.9693    −0.0050--0.0967              0.9970   0.0204
  Kehua                 Y = 0.8949X + 0.2585   0.8674--0.8901    0.2159--0.3141               0.9967   0.0207
  Reebio                Y = 0.9032X + 0.1382   0.8896--0.9168    0.073--0.1971                0.9956   0.0236
  Biosino               Y = 1.0392X − 0.1762   0.8896--0.9168    0.0793--0.1971               0.9980   0.0183

*CI*: Confidence interval.

**Mean bias and scope**

For the 14 routine methods, the mean bias and range of the 48 patient samples are listed in [Table 3](#T3){ref-type="table"}. For the Roche, Beijing Strong, Mindray, and Kehua assays, the mean bias met the desired bias of 2% and 1.30%. Because the samples with extremely low and high concentrations were difficult to obtain, the concentrations of the 48 fresh serum samples did not cover the three medical decision levels. Therefore, we used the lowest concentration (1.83 mmol/L), highest concentration (3.10 mmol/L), and mean concentration (2.47 mmol/L) to evaluate accuracy. For most assays, the bias at the three concentration levels met the desired bias of CLIA\'88; for nearly half of the assays, the bias met the desired limit of 2%. Only a few assays met the minimum performance specification derived from biological variation (1.3%). For the Mindray assay, the bias at the three concentration levels met the desired bias of 1.3%. For the Roche and Beijing Strong assays, the bias at the three medical decision levels all met the desired bias of 2%. The prediction bias for the three medical decision levels is given in [Table 4](#T4){ref-type="table"}.

###### 

The mean bias and slope of the 48 patient samples for the 14 routine methods

  Assays            Absolute bias             Relative bias                          
  ----------------- ------------------------- --------------- ---------------------- --------------
  Roche             −0.022 (−0.022--−0.021)   −0.05--0.013    −0.90 (−0.94--−0.87)   −2.48--0.74
  Diasys            −0.079 (−0.080--−0.078)   −0.16--−0.04    −3.42 (−3.46--−3.39)   −5.23--−1.78
  Wako              −0.074 (−0.075--−0.073)   −0.12--0.05     −3.28 (−3.34--−3.22)   −5.64--2.76
  Medical system    −0.047 (−0.049--−0.046)   −0.12--0.05     −2.02 (−2.08--−1.97)   −4.94--2.34
  Sichuan Maccura   −0.129 (−0.131--−0.128)   −0.16--0.04     −5.61 (−5.69--−5.54)   −8.52--1.65
  Beijing strong    −0.019 (−0.020--−0.018)   −0.07--0.02     −0.85 (−0.90--−0.81)   −3.97--1.01
  DIRUI             −0.050 (−0.049--−0.051)   −0.09--0.01     −2.30 (−2.35--−2.24)   −5.04--0.26
  Leadman           −0.069 (−0.070--−0.067)   −0.11--0.02     −2.97 (−2.02--−2.90)   −6.07--0.84
  Mindray           −0.001 (−0.002--0.000)    −0.03--0.05     −0.01 (−0.04--0.05)    −1.83--2.52
  Long March I      −0.049 (−0.051--−0.047)   −0.12--0.09     −2.30 (−2.37--−2.23)   −5.81--2.92
  Long March II     −0.052 (−0.053--−0.051)   −0.12--−0.01    −2.23 (−2.26--−2.19)   −3.92--−0.43
  Kehua             −0.013 (−0.015--−0.012)   −0.14--0.05     −0.43 (−0.49--−0.36)   −4.41--2.65
  Reebio            −0.084 (−0.086--−0.083)   −0.14--0.04     −3.58 (−3.63--−3.53)   −5.45--1.65
  Biosino           −0.086 (−0.087--−0.085)   −0.12--−0.02    −3.86 (−3.91--−3.81)   −5.62--−0.99

*CI*: Confidence interval.

###### 

Expected bias for three medical decision levels

  Assays                       1.83 mmol/L            2.47 mmol/L                                     
  ---------------------------- ---------------------- ----------------------- ----------------------- ----------------------
  Roche                        −0.01 (−0.02--0.00)    −0.33 (−0.92--0.26)     −0.03 (−0.04--−−0.02)   −1.11 (−1.48--−0.74)
  Diasys                       −0.06 (−0.07--−0.04)   −3.10 (−3.72--−2.30)    −0.09 (−0.10--−0.08)    −3.56 (−4.01--−3.11)
  Wako                         −0.07 (−0.09--−0.06)   −4.07 (−5.03--−3.11)    −0.07 (−0.09--−0.06)    −3.01 (−3.62--−2.40)
  Medical system               −0.03 (−0.07--−0.04)   −1.39 (−2.39--0.39)     −0.06 (−0.07--−0.04)    −2.26 (−2.89--−1.62)
  Sichuan Maccura              −0.09 (−0.12--−0.07)   −5.04 (−6.42--−3.66)    −0.14 (−0.16--−0.12)    −5.80 (−6.68--−4.93)
  Beijing strong               −0.03 (−0.04--−0.01)   −1.49 (−2.30--−0.68)    −0.02 (−0.03--0.00)     −0.62 (−1.13--−0.11)
  DIRUI                        −0.07 (−0.09--−0.06)   −4.05 (−4.76--−3.33)    −0.04 (−0.05--−0.03)    −1.68 (−2.13--−1.23)
  Leadman                      −0.04 (−0.07--−0.02)   −2.38 (−3.57--−1.19)    −0.08 (−0.10--−0.06)    −3.15 (−3.91--−2.40)
  Mindray                      0.02 (0.00--0.03)      0.89 (0.12--1.66)       −0.01 (−0.02--0.00)     −0.30 (−0.79--0.19)
  Long March I                 −0.10 (−0.11--−0.08)   −5.42 (−6.28--−4.55)    −0.03 (−0.04--−0.02)    −1.22 (−1.77--−0.67)
  Long March II                −0.03 (−0.05--−0.02)   −1.74 (−2.47--1.01)     −0.06 (−0.07--−0.05)    −2.39 (−2.85--−1.92)
  Kehua                        0.04 (0.03--0.06)      2.35 (1.65--3.06)       −0.03 (−0.05--−0.02)    −1.40 (−1.85--−0.95)
  Reebio                       −0.04 (−0.05--−0.02)   −2.13 (−2.98--−1.28)    −0.10 (−0.11--−0.09)    −4.09 (−4.63--−3.55)
  Biosino                      −0.10 (−0.12--−0.09)   −5.71 (−6.36--−5.05)    −0.08 (−0.09--−0.07)    −3.21 (−3.63--−2.80)
  Meet 2%                                             5                                               6
  Meet 1.3%                                           2                                               4
                                                                                                      
  **Assays**                   **3.10 mmol/L**                                                        
                                                                                                      
  **Absolute bias (mmol/L)**                          **Relative bias (%)**                           
                                                                                                      
  Roche                                               −0.05 (−0.07--−0.03)                            −1.56 (−2.19--−0.93)
  Diasys                                              −0.12 (−0.14--−0.10)                            −3.88 (−4.64--−3.11)
  Wako                                                −0.07 (−0.11--−0.04)                            −2.39 (−3.42--−1.37)
  Medical system                                      −0.09 (−0.12--−0.05)                            −2.76 (−3.84--−1.69)
  Sichuan Maccura                                     −0.19 (−0.24--−0.15)                            −6.24 (−7.73--−4.76)
  Beijing strong                                      0.00 (−0.03--0.02)                              −0.11 (−0.98--0.76)
  DIRUI                                               −0.01 (−0.03--0.01)                             −0.30 (−1.07--0.46)
  Leadman                                             −0.11 (−0.15--−0.07)                            −3.60 (−4.88--−2.32)
  Mindray                                             −0.03 (−0.06--0.00)                             −0.99 (−1.82--−0.16)
  Long March I                                        0.04 (0.01--0.07)                               1.22 (0.29--2.15)
  Long March II                                       −0.09 (−0.11--−0.06)                            −2.77 (−3.55--−1.98)
  Kehua                                               −0.11 (−0.13--−0.09)                            −3.58 (−4.34--2.82)
  Ge                                                  −0.16 (−0.19--−0.13)                            −5.23 (−6.14--−4.31)
  Biosino                                             −0.05 (−0.08--−0.03)                            −1.76 (−2.47--−1.06)
  Meet 2%                                                                                             6
  Meet 1.3%                                                                                           4

The bias is the difference between the expected value calculated by the regression line and the target value (the result of ICP-MS). The range in brackets is the 95% *CI* of the bias. The two criteria used to evaluate bias were the minimum performance standard based on biological variation (1.3%) and the expanded tolerance limits based on biological variation and current measurement level (2%). ICP-MS: Inductively coupled plasma-mass spectrometry; *CI*: Confidence interval.

**Trend of relative bias**

For the 14 routine methods, the relative bias exhibited four primary trends. The Roche, Beijing Strong, and Mindray assays exhibited both negative and positive bias. The bias at the three concentration levels was quite small, indicating that the calibration bias can almost be ignored and that the accuracy of the methods was sufficient \[[Figure 1a](#F1){ref-type="fig"}, Roche assay\]. For the Diasys, Wako, Medical System, Sichuan Maccura, Leadman, Long March II, Reebio, and Biosino assays, negative biases were dominant \[[Figure 1b](#F1){ref-type="fig"}, Sichuan Maccura\]. For DIRUI and Long March I, the slope was large, indicating that negative bias existed at low concentrations, whereas positive bias existed at high concentrations \[[Figure 1c](#F1){ref-type="fig"}, Long March I\]. For the Kehua assay, the slope was small, and the intercept was large; therefore, positive bias existed at low levels, and negative bias existed at high levels \[[Figure 1d](#F1){ref-type="fig"}, Kehua\].

![The relative bias of routine methods (a: Roche assay; b: Sichuan Maccura; c: Long March I; d: Kehua) compared with the reference method. The result of the comparative methods is on the X-axis, the relative bias of the routine method is on the Y-axis. The line designated 1.27% (the orange dotted line) was determined by the minimal bias specifications derived from biological variation; the line designated 2% was the expanded tolerance bias derived from biological variation and the current quality condition.](CMJ-131-1584-g001){#F1}

For the DIRUI, Long March I, Kehua, and Biosino assays, the bias changed with the concentration, and the mean bias did not reflect the actual level of the assays. Therefore, careful attention should be paid to the bias at three concentration levels because the bias changed over the measurement interval in a linear manner, and the difference plot could be analyzed through ordinary linear regression.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

EQA was introduced into laboratory medicine as an educational tool to address observations that the measurement results for aliquots of the same sample are often different when measured by different laboratories. Although many different and frequently proprietary procedures are used by manufacturers to obtain PT/EQA samples with suitable analyte quantities and stability characteristics for storage and distribution, the commutability is generally unknown. The present study showed that 2013 EQA and 2014 EQA materials exhibited matrix effects in some assays. In EQA schemes, the most common procedure used to assign a target value was to categorize participant methods into "peer groups" that represented a similar technology and to calculate the mean or median of the peer group as the target value; however, this method may not be able to detect an error by a manufacturer when the supplied calibrators in a region are affected.\[[@ref11][@ref12]\] The sample volume required in EQA schemes is large, the preparation of human serum pools is difficult, and their transportation costs are high compared with those of lyophilized serum. Therefore, lyophilized serum is more practical and could not be replaced. Accordingly, these EQA schemes should include at least one human serum pool sample to enable proper interpretation of the EQA results.\[[@ref13]\]

Secondary calibrators serve as an important medium for quantifying traceability and that should be traceable to the primary reference material or method and should be commutable with patient samples. The manufacturers generally validate the commutability of their calibrators to yield measurement results with traceability to the highest metrological standard.\[[@ref5]\] In China, more than half of the laboratories use the heterogeneous system. If the calibrators lack commutability, using the same value as a constant value may affect the validity of the measurement assay. In this study, the matrices of the 14 supporting calibrators were different. For the Diasys, Medical system, DIRUI, Kehua, and Reebio assays, the matrix of the calibrators was an aqueous solution, whereas for the other assays, the matrix of the calibrators was lyophilized serum. For all 14 supporting calibrators, the matrix was different from fresh serum and the commutability was unknown. Furthermore, four calibrators (Imported A, Imported B, domestic A, and domestic B) commonly used in China showed a matrix effect in some assays. Therefore, laboratories using heterogeneous systems should verify the traceability of the measurement results.\[[@ref14]\]

Commutability is relevant to the general materials and methods of a measurement protocol. In this study, with the exception of the aqueous reference materials, all of the processed materials were commutable in the Medical system, DIRUI, and Reebio assays, indicating that the specificity of these assays was high. For the Diasys assay, nine processed materials showed matrix effects, indicating that the specificity of the assay may need improvement. We should note that the standard to evaluate the matrix effect is based on whether a significant statistical difference was found; thus, the premise of the conclusion was that the precision of all of the assays (Sy.x) was consistent.

In the study, we evaluated the calibration bias based on the results of 48 patient serum samples. The correlation coefficient was \>0.99 for most assays, and the slope was close to 1. The intercept ranged from −0.2964 mmol/L to 0.1382 mmol/L, and most of the intercept values were close to ±0.1 mmol/L. This finding indicated that the specificity of most assays was sufficient, but some assays still exhibited calibration bias. For the Roche, Beijing Strong, and Mindray assays, the bias at the three concentration levels was within 2%, indicating that the accuracy of these assays was good.

In this study, all of the assays used reagents and their supporting calibrators such that the presence of calibrator bias may originate from the inaccurately assigned value of the calibrators. For most assays, the assigned value of calibrators could be traced to the reference materials such as SRM909b, GBW09152, and CERI JCSS calcium standard solution, and the commutability of these reference materials was unknown. Only the calibrator of the Diasys assay was traced to the reference method, namely, atomic absorption spectroscopy. Using reference materials, lacking in commutability to assign the values of the routine calibrators may affect the accuracy of the method. Therefore, several researchers recommend using the reference method instead of reference materials to assign values of the routine calibrators.\[[@ref15]\] For most manufacturers, the detailed information of the procedure to assign the values of routine calibrators is not provided; therefore, the laboratories cannot know if the traceability chain has been maintained. The traceability standards in the *in vitro* diagnostic instruments directive (Directive 98/79/EC) as well as ISO17511 and ISO18153\[[@ref16]\] are all relevant to diagnostic equipment manufacturers.

One of the main limitations of this study is that all of the assays were performed using the Hitachi 7180 automatic biochemical analyzer. For each assay, we only used one lot reagent and calibrator, and therefore accidental errors may have occurred when performing these assays.

Because the samples with extremely low and high concentration were difficult to collect (i.e., the concentration range of the 48 fresh serum samples was 1.83--3.10 mmol/L), we can only select the processed materials within the limited concentration range for evaluation. Furthermore, the concentration range did not cover the three medical decision levels; therefore, we used the lowest concentration (1.83 mmol/L), highest concentration (3.10 mmol/L), and the concentration (2.47 mmol/L) of the patient samples to evaluate the accuracy with respect to these three levels.

In conclusion, we determined that some processed materials display the matrix effect, which should be considered during interpretation. Most routine methods have high specificity; however, the trueness of some assays needs improvement. Using the reference method to evaluate the matrix effect and calibration bias may help to promote the standardization of measurements of the serum calcium concentration.
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